Drug Profile

MT 4561

Alternative Names: MT-4561

Latest Information Update: 06 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Mitsubishi Tanabe Pharma Corporation
Class Antineoplastics
Mechanism of Action Bromodomain containing protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I/II Solid tumours
Preclinical Acute myeloid leukaemia

Most Recent Events

30 Apr 2025 Mitsubishi Tanabe Pharma America plans a phase I/II trial for Solid tumours (Late-stage disease) in USA (IV, Infusion) in April 2025 (NCT06943521)
18 Apr 2025 Phase-I/II clinical trials in Solid tumours (Late-stage disease) in USA (IV) (NCT06943521)
23 Oct 2024 Preclinical trials in Acute myeloid leukaemia in Japan (unspecified route), prior to October 2024

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com